Healthcare stocks are holding on to narrow gains, with the NYSE
Healthcare Sector Index gaining less than 0.1% and shares of
healthcare companies in the S&P 500 adding about 0.2% as a
In company news, MacroGenics (
) enjoyed a modest uptick before falling negative in recent trade
after presenting pre-clinical data today on its proprietary
anti-CD3 antibody and an antibody to CD123 to redirect T cells
against CD123-positive acute myeloid leukemia cells.
According to the company, the investigators found that the
anti-bodies combination eliminated more than 97% of the leukemia
cells in mice engrafted with a leukemia patient sample.
They also observed significant clearing from the spleen and bone
marrow six weeks after the cell infusions, stating the results
provide a strong rationale for the clinical development of the
anti-bodies as a novel molecule to treat leukemia patients.
MGNX shares are down about 0.2% at $25.95 each in late trade,
earlier climbing as high as $27.00 this morning prior to its
mid-day presentation at 55th Annual Meeting of the American Society
of Hematology in New Orleans.
In other sector news,
(+) GIVN, Accepts $860-million buyout offer from Covidien (
), with GIVN shareholders receiving $30 in cash for each share they
now own. COV said it expects the deal will immediately add to its
earnings, adding up to $50 million in annual revenue.
(-) PGNX, Late Friday released Phase I data for its
TC-99-M-MIP-1404 SPECT/CT imaging agent, saying it correctly
identified eight out of eight patients with prostate cancer in a
poster presentation to the Society for Urologic Oncology in